BioNexus Gene Lab (BGLC) Current Assets (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Current Assets data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 20.58% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 20.58% YoY), and the FY2025 full-year result was $5.4 million, down 26.67% from the prior year.
• Current Assets eased to $5.2 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $8.3 million in Q3 2023 to a low of $5.2 million in Q1 2026.
• A 5-year average of $6.5 million and a median of $6.4 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets retreated 26.93% in 2022 and jumped 52.89% in 2023, its largest moves.
• Tracing BGLC's Current Assets over 5 years: stood at $6.0 million in 2022, then surged by 33.63% to $8.0 million in 2023, then dropped by 7.66% to $7.4 million in 2024, then slipped by 26.67% to $5.4 million in 2025, then declined by 4.64% to $5.2 million in 2026.
• Business Quant data shows BGLC's Current Assets at $5.2 million in Q1 2026, $5.4 million in Q4 2025, and $5.6 million in Q3 2025.